These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 22888218)

  • 21. Clinical pharmacokinetics of fingolimod.
    David OJ; Kovarik JM; Schmouder RL
    Clin Pharmacokinet; 2012 Jan; 51(1):15-28. PubMed ID: 22149256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.
    Yeh EA; Weinstock-Guttman B
    Adv Ther; 2011 Apr; 28(4):270-8. PubMed ID: 21394595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapeutic effect of S1P receptor modifying drugs for autoimmune diseases].
    Chiba K; Kataoka H
    Nihon Yakurigaku Zasshi; 2008 Mar; 131(3):24-5. PubMed ID: 18421849
    [No Abstract]   [Full Text] [Related]  

  • 24. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
    Lee CW; Choi JW; Chun J
    Arch Pharm Res; 2010 Oct; 33(10):1567-74. PubMed ID: 21052934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trial watch: Phase III promise for oral multiple sclerosis therapy.
    Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180099
    [No Abstract]   [Full Text] [Related]  

  • 26. The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators.
    Soliven B; Miron V; Chun J
    Neurology; 2011 Feb; 76(8 Suppl 3):S9-14. PubMed ID: 21339490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
    Cohen JA; Chun J
    Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FTY720 and central memory: out of sight, out of mind.
    Slavin AJ; Zamvil SS
    Neurology; 2010 Aug; 75(5):388-9. PubMed ID: 20610831
    [No Abstract]   [Full Text] [Related]  

  • 29. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo.
    Hu Y; Lee X; Ji B; Guckian K; Apicco D; Pepinsky RB; Miller RH; Mi S
    Mol Cell Neurosci; 2011 Sep; 48(1):72-81. PubMed ID: 21740973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.
    Brinkmann V; Billich A; Baumruker T; Heining P; Schmouder R; Francis G; Aradhye S; Burtin P
    Nat Rev Drug Discov; 2010 Nov; 9(11):883-97. PubMed ID: 21031003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
    Singer B; Ross AP; Tobias K
    Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
    Choi JW; Gardell SE; Herr DR; Rivera R; Lee CW; Noguchi K; Teo ST; Yung YC; Lu M; Kennedy G; Chun J
    Proc Natl Acad Sci U S A; 2011 Jan; 108(2):751-6. PubMed ID: 21177428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Research progress of the selective sphingosine-1-phosphate receptor 1 agonists].
    Tian YL; Jin J; Wang XJ
    Yao Xue Xue Bao; 2012 Jan; 47(1):7-17. PubMed ID: 22493799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [New therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
    Chiba K
    Yakugaku Zasshi; 2009 Jun; 129(6):655-65. PubMed ID: 19483408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation.
    Hla T; Brinkmann V
    Neurology; 2011 Feb; 76(8 Suppl 3):S3-8. PubMed ID: 21339489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Infections and fingolimod].
    Cervera C
    Rev Neurol; 2012 Aug; 55(4):227-37. PubMed ID: 22829086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.
    Fazekas F; Berger T; Fabjan TH; Ledinek AH; Jakab G; Komoly S; Kraus J; Kurča E; Kyriakides T; Lisý L; Milanov I; Panayiotou P; Jazbec SS; Taláb R; Traykov L; Turčáni P; Vass K; Vella N; Havrdová E
    Wien Med Wochenschr; 2012 Aug; 162(15-16):354-66. PubMed ID: 22895849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature].
    Shmyrev VI; Kryzhanovskiĭ SM; Danilycheva IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):93-7. PubMed ID: 22677684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Future clinical challenges in multiple sclerosis: Relevance to sphingosine 1-phosphate receptor modulator therapy.
    Hohlfeld R; Barkhof F; Polman C
    Neurology; 2011 Feb; 76(8 Suppl 3):S28-37. PubMed ID: 21339488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.